{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T20:12:29Z","timestamp":1775074349308,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s13075-016-1214-8","type":"journal-article","created":{"date-parts":[[2017,1,19]],"date-time":"2017-01-19T15:18:14Z","timestamp":1484839094000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["Clinical significance of soluble CD163 in polymyositis-related or dermatomyositis-related interstitial lung disease"],"prefix":"10.1186","volume":"19","author":[{"given":"Yasunori","family":"Enomoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuzo","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hironao","family":"Hozumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazutaka","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Kono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Karayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuki","family":"Furuhashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoyuki","family":"Fujisawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriyuki","family":"Enomoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaro","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Inui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriyoshi","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ran","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsuneyo","family":"Mimori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihide","family":"Iwashita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takafumi","family":"Suda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,1,19]]},"reference":[{"key":"1214_CR1","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.mayocp.2012.10.017","volume":"88","author":"FC Ernste","year":"2013","unstructured":"Ernste FC, Reed AM. Idiopathic inflammatory myopathies: current trends in pathogenesis, clinical features, and up-to-date treatment recommendations. Mayo Clin Proc. 2013;88:83\u2013105.","journal-title":"Mayo Clin Proc"},{"key":"1214_CR2","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJM197502132920706","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292:344\u20137.","journal-title":"N Engl J Med"},{"key":"1214_CR3","doi-asserted-by":"crossref","first-page":"h6819","DOI":"10.1136\/bmj.h6819","volume":"352","author":"SC Mathai","year":"2016","unstructured":"Mathai SC, Danoff SK. Management of interstitial lung disease associated with connective tissue disease. BMJ. 2016;352:h6819.","journal-title":"BMJ"},{"key":"1214_CR4","first-page":"58","volume":"32","author":"T Fujisawa","year":"2005","unstructured":"Fujisawa T, Suda T, Nakamura Y, Enomoto N, Ide K, Toyoshima M, et al. Differences in clinical features and prognosis of interstitial lung diseases between polymyositis and dermatomyositis. J Rheumatol. 2005;32:58\u201364.","journal-title":"J Rheumatol"},{"key":"1214_CR5","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1183\/09031936.06.00038806","volume":"28","author":"T Suda","year":"2006","unstructured":"Suda T, Fujisawa T, Enomoto N, Nakamura Y, Inui N, Naito T, et al. Interstitial lung diseases associated with amyopathic dermatomyositis. Eur Respir J. 2006;28:1005\u201312.","journal-title":"Eur Respir J"},{"key":"1214_CR6","doi-asserted-by":"crossref","first-page":"e98824","DOI":"10.1371\/journal.pone.0098824","volume":"9","author":"T Fujisawa","year":"2014","unstructured":"Fujisawa T, Hozumi H, Kono M, Enomoto N, Hashimoto D, Nakamura Y, et al. Prognostic factors for myositis-associated interstitial lung disease. PLoS One. 2014;9:e98824.","journal-title":"PLoS One"},{"key":"1214_CR7","doi-asserted-by":"crossref","first-page":"e0120313","DOI":"10.1371\/journal.pone.0120313","volume":"10","author":"H Hozumi","year":"2015","unstructured":"Hozumi H, Enomoto N, Kono M, Fujisawa T, Inui N, Nakamura Y, et al. Prognostic significance of anti-aminoacyl-tRNA synthetase antibodies in polymyositis\/dermatomyositis-associated interstitial lung disease: a retrospective case control study. PLoS One. 2015;10:e0120313.","journal-title":"PLoS One"},{"key":"1214_CR8","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/s12890-016-0325-y","volume":"16","author":"H Sasano","year":"2016","unstructured":"Sasano H, Hagiwara E, Kitamura H, Enomoto Y, Matsuo N, Baba T, et al. Long-term clinical course of anti-glycyl tRNA synthetase (anti-EJ) antibody-related interstitial lung disease pathologically proven by surgical lung biopsy. BMC Pulm Med. 2016;16:168.","journal-title":"BMC Pulm Med"},{"key":"1214_CR9","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.imbio.2005.05.010","volume":"210","author":"BO Fabriek","year":"2005","unstructured":"Fabriek BO, Dijkstra CD, van den Berg TK. The macrophage scavenger receptor CD163. Immunobiology. 2005;210:153\u201360.","journal-title":"Immunobiology"},{"key":"1214_CR10","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1309\/QHD6YFN81KQXUUH6","volume":"122","author":"SK Lau","year":"2004","unstructured":"Lau SK, Chu PG, Weiss LM. CD163: a specific marker of macrophages in paraffin-embedded tissue samples. Am J Clin Pathol. 2004;122:794\u2013801.","journal-title":"Am J Clin Pathol"},{"key":"1214_CR11","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1089\/ars.2012.4834","volume":"18","author":"A Etzerodt","year":"2013","unstructured":"Etzerodt A, Moestrup SK. CD163 and inflammation: biological, diagnostic, and therapeutic aspects. Antioxid Redox Signal. 2013;18:2352\u201363.","journal-title":"Antioxid Redox Signal"},{"key":"1214_CR12","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1136\/ard.2005.051086","volume":"65","author":"C Dorph","year":"2006","unstructured":"Dorph C, Englund P, Nennesmo I, Lundberg IE. Signs of inflammation in both symptomatic and asymptomatic muscles from patients with polymyositis and dermatomyositis. Ann Rheum Dis. 2006;65:1565\u201371.","journal-title":"Ann Rheum Dis"},{"key":"1214_CR13","doi-asserted-by":"crossref","first-page":"979","DOI":"10.3899\/jrheum.141307","volume":"42","author":"QL Peng","year":"2015","unstructured":"Peng QL, Zhang YL, Shu XM, Yang HB, Zhang L, Chen F, et al. Elevated serum levels of soluble CD163 in polymyositis and dermatomyositis: associated with macrophage infiltration in muscle tissue. J Rheumatol. 2015;42:979\u201387.","journal-title":"J Rheumatol"},{"key":"1214_CR14","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(03)14368-1","volume":"362","author":"MC Dalakas","year":"2003","unstructured":"Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet. 2003;362:971\u201382.","journal-title":"Lancet"},{"key":"1214_CR15","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/ncprheum0140","volume":"2","author":"MC Dalakas","year":"2006","unstructured":"Dalakas MC. Mechanisms of disease: signaling pathways and immunobiology of inflammatory myopathies. Nat Clin Pract Rheumatol. 2006;2:219\u201327.","journal-title":"Nat Clin Pract Rheumatol"},{"key":"1214_CR16","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1084\/jem.170.3.727","volume":"170","author":"N Khalil","year":"1989","unstructured":"Khalil N, Bereznay O, Sporn M, Greenberg AH. Macrophage production of transforming growth factor beta and fibroblast collagen synthesis in chronic pulmonary inflammation. J Exp Med. 1989;170:727\u201337.","journal-title":"J Exp Med"},{"key":"1214_CR17","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1164\/rccm.201010-1719OC","volume":"184","author":"MA Gibbons","year":"2011","unstructured":"Gibbons MA, MacKinnon AC, Ramachandran P, Dhaliwal K, Duffin R, Phythian-Adams AT, et al. Ly6Chi monocytes direct alternatively activated profibrotic macrophage regulation of lung fibrosis. Am J Respir Crit Care Med. 2011;184:569\u201381.","journal-title":"Am J Respir Crit Care Med"},{"key":"1214_CR18","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1097\/01.CCM.0000239120.32490.AB","volume":"34","author":"HJ M\u00f8ller","year":"2006","unstructured":"M\u00f8ller HJ, Moestrup SK, Weis N, Wejse C, Nielsen H, Pedersen SS, et al. Macrophage serum markers in pneumococcal bacteremia: prediction of survival by soluble CD163. Crit Care Med. 2006;34:2561\u20136.","journal-title":"Crit Care Med"},{"key":"1214_CR19","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jinf.2016.07.004","volume":"73","author":"Y Suzuki","year":"2016","unstructured":"Suzuki Y, Enomoto Y, Yokomura K, Hozumi H, Kono M, Karayama M, et al. Soluble hemoglobin scavenger receptor CD163 (sCD163) predicts mortality of community-acquired pneumonia. J Infect. 2016;73:375\u20137.","journal-title":"J Infect"},{"key":"1214_CR20","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1128\/CVI.00506-07","volume":"15","author":"KA Kusi","year":"2008","unstructured":"Kusi KA, Gyan BA, Goka BQ, Dodoo D, Obeng-Adjei G, Troye-Blomberg M, et al. Levels of soluble CD163 and severity of malaria in children in Ghana. Clin Vaccine Immunol. 2008;15:1456\u201360.","journal-title":"Clin Vaccine Immunol"},{"key":"1214_CR21","first-page":"689","volume":"29","author":"SR Greisen","year":"2011","unstructured":"Greisen SR, Moller HJ, Stengaard-Pedersen K, Hetland ML, H\u00f8rslev-Petersen K, J\u00f8rgensen A, et al. Soluble macrophage-derived CD163 is a marker of disease activity and progression in early rheumatoid arthritis. Clin Exp Rheumatol. 2011;29:689\u201392.","journal-title":"Clin Exp Rheumatol"},{"key":"1214_CR22","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s00296-010-1691-z","volume":"32","author":"W Nakayama","year":"2012","unstructured":"Nakayama W, Jinnin M, Makino K, Kajihara I, Makino T, Fukushima S, et al. Serum levels of soluble CD163 in patients with systemic sclerosis. Rheumatol Int. 2012;32:403\u20137.","journal-title":"Rheumatol Int"},{"issue":"1","key":"1214_CR23","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1513\/AnnalsATS.201607-528OC","volume":"14","author":"Y Suzuki","year":"2017","unstructured":"Suzuki Y, Shirai M, Asada K, Miwa S, Karayama M, Nakamura Y, et al. Utility of macrophage activated marker, CD163, for diagnosis and prognosis in pulmonary tuberculosis. Ann Am Thorac Soc. 2017;14(1):57\u201364.","journal-title":"Ann Am Thorac Soc"},{"key":"1214_CR24","doi-asserted-by":"crossref","first-page":"124S","DOI":"10.1038\/jid.1993.35","volume":"100","author":"RL Euwer","year":"1993","unstructured":"Euwer RL, Sontheimer RD. Amyopathic dermatomyositis: a review. J Invest Dermatol. 1993;100:124S\u20137S.","journal-title":"J Invest Dermatol"},{"key":"1214_CR25","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1164\/rccm.200706-877OC","volume":"177","author":"NS Goh","year":"2008","unstructured":"Goh NS, Desai SR, Veeraraghavan S, Hansell DM, Copley SJ, Maher TM, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med. 2008;177:1248\u201354.","journal-title":"Am J Respir Crit Care Med"},{"key":"1214_CR26","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.0006-341X.2005.030814.x","volume":"61","author":"PJ Heagerty","year":"2005","unstructured":"Heagerty PJ, Zheng Y. Survival model predictive accuracy and ROC curves. Biometrics. 2005;61:92\u2013105.","journal-title":"Biometrics"},{"key":"1214_CR27","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1093\/rheumatology\/kes102","volume":"51","author":"T Gono","year":"2012","unstructured":"Gono T, Sato S, Kawaguchi Y, Kuwana M, Hanaoka M, Katsumata Y, et al. Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Rheumatology (Oxford). 2012;51:1563\u201370.","journal-title":"Rheumatology (Oxford)"},{"key":"1214_CR28","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s10067-015-2866-5","volume":"34","author":"J Zou","year":"2015","unstructured":"Zou J, Guo Q, Chi J, Wu H, Bao C. HRCT score and serum ferritin level are factors associated to the 1-year mortality of acute interstitial lung disease in clinically amyopathic dermatomyositis patients. Clin Rheumatol. 2015;34:707\u201314.","journal-title":"Clin Rheumatol"},{"key":"1214_CR29","doi-asserted-by":"crossref","first-page":"e89610","DOI":"10.1371\/journal.pone.0089610","volume":"9","author":"K Isoda","year":"2014","unstructured":"Isoda K, Takeuchi T, Kotani T, Hata K, Shoda T, Ishida T, et al. Pre-treatment ferritin level and alveolar-arterial oxygen gradient can predict mortality rate due to acute\/subacute interstitial pneumonia in dermatomyositis treated by cyclosporine a\/glucocorticosteroid combination therapy: a case control study [corrected]. PLoS One. 2014;9:e89610.","journal-title":"PLoS One"},{"key":"1214_CR30","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.cytogfr.2004.03.006","volume":"15","author":"JC Bonner","year":"2004","unstructured":"Bonner JC. Regulation of PDGF and its receptors in fibrotic diseases. Cytokine Growth Factor Rev. 2004;15:255\u201373.","journal-title":"Cytokine Growth Factor Rev"},{"key":"1214_CR31","first-page":"1189","volume":"143","author":"C Henke","year":"1993","unstructured":"Henke C, Marineili W, Jessurun J, Fox J, Harms D, Peterson M, et al. Macrophage production of basic fibroblast growth factor in the fibroproliferative disorder of alveolar fibrosis after lung injury. Am J Pathol. 1993;143:1189\u201399.","journal-title":"Am J Pathol"}],"container-title":["Arthritis Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-016-1214-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T08:36:59Z","timestamp":1498379819000},"score":1,"resource":{"primary":{"URL":"http:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-016-1214-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,19]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["1214"],"URL":"https:\/\/doi.org\/10.1186\/s13075-016-1214-8","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,19]]},"article-number":"9"}}